Related Experiment Videos
[Current therapeutic means]
Florence Trémollières1, Jean-Michel Pouillès, Claude Ribot
1Unité Ménopause et Maladies Osseuses Métaboliques, service d'Endocrinologie, CHU Rangueil, 31403 Toulouse. tremollieres.f@chu-toulouse.fr
Presse Medicale (Paris, France : 1983)
|August 1, 2002
Summary
New osteoporosis treatments offer fracture prevention for high-risk women. Bone density testing is crucial before initiating therapy, despite challenges in official recognition and reimbursement for these advanced osteoporosis drugs.
Area of Science:
- Endocrinology and Metabolic Bone Diseases
- Pharmacology of Bone Therapeutics
Context:
- Osteoporosis treatment has advanced significantly with new drug classes beyond hormone replacement therapy (HRT).
- Second and third-generation bisphosphonates and raloxifene are available for primary and secondary fracture prevention.
Purpose:
- To evaluate the indications and efficacy of modern osteoporosis therapeutics.
- To discuss the practical challenges in implementing these treatments, particularly for high-risk individuals.
Summary:
- Anti-fracture efficacy of new osteoporosis drugs is primarily observed in postmenopausal women with a T-score < -2.5 and prevalent fractures.
- Bone density measurement is recommended before initiating treatment, but official recognition and reimbursement vary.
- These factors contribute to challenges in treating high-risk women who have not yet experienced a fracture.
Impact:
- Highlights the need for standardized guidelines and recognition of bone density testing for effective osteoporosis management.
- Emphasizes the importance of identifying and treating high-risk individuals to prevent fragility fractures.
- Informs clinical practice regarding the appropriate use of advanced osteoporosis therapies.